Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 25, 2023

Efficacy and Safety of Disitamab Vedotin in Patients With HER2-Positive Locally Advanced or Metastatic Urothelial Carcinoma

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials
J. Clin. Oncol 2023 Nov 21;[EPub Ahead of Print], X Sheng, L Wang, Z He, Y Shi, H Luo, W Han, X Yao, B Shi, J Liu, C Hu, Z Liu, H Guo, G Yu, Z Ji, J Ying, Y Ling, S Yu, Y Hu, J Guo, J Fang, A Zhou, J Guo

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading